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Abstract
Several genetic variations have been associated with Parkinson disease in different populations over the past few years.
Although a considerable number of worldwide populations have been screened for these variants, results from Sub-Saharan
populations are very scarce in the literature. In the present report we have screened a cohort of Parkinson disease patients
(n = 57) and healthy controls (n = 51) from Nigeria for mutations in the genes PRKN, LRRK2 and ATXN3. No pathogenic
mutations were found in any of the genes. Hence, common pathogenic mutations in these genes, observed in several
different populations, are not a frequent cause of Parkinson disease in Nigeria.
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Introduction
The identification of monogenic causes of Parkinson’s disease
(PD) (MIM #168600) has improved our understanding of the
pathogenesis of the disease and promises to facilitate the
development of biomarkers to aid early diagnosis and interven-
tions that may slow disease progression or even provide a cure in
the future. Mutations in two genes have been linked to autosomal
dominant PD; the first, encoding a-synuclein (SNCA; MIM
#163890; PARK1) [1] and the second encoding leucine-rich
repeat kinase 2 (LRRK2; MIM #609007; PARK8) [2,3].
Mutations in three genes have been linked to autosomal recessive
PD: the gene encoding parkin (PRKN; MIM #602544;
PARK2)[4], the gene encoding PTEN – induced kinase 1
(PINK1; MIM #608309; PARK6) [5] and the gene encoding
DJ-1 (PARK7; MIM #602533; PARK7) [6]. In addition,
pathogenic repeat expansion mutations in the genes encoding
ataxin-3 (ATXN3; MIM #109150) [7] and ataxin-2 (ATXN2;
MIM #183090) [8] have been described as autosomal dominant
causes of PD.
The frequency of mutations and the risk attributable to
polymorphisms in LRRK2, PRKN and ATXN3 in patients with
sporadic PD has been explored in several studies. Mutations in
LRRK2, specifically G2019S, appear to be the most common
known genetic lesion underlying PD (including the apparently
sporadic form), with frequencies as high as 6% in the European
population [9] and 41% in North African Arabs [10]. The gene
LRRK2 on chromosome 12q12 encodes a primarily cytoplasmic
protein kinase, the function of which has not been clearly
elucidated. Parkin is a ubiquitin-protein ligase that maps to
chromosome 6q25.2–q27 [14]. Mutations in PRKN have been
reported as the most frequent cause of autosomal recessive juvenile
onset familial PD [11]. However, studies investigating the role of
genetic variability at the PRKN locus in determining susceptibility
to sporadic PD have provided differing results [12,13]. A wide
variety of mutations have been described in PRKN, ranging from
point mutations to whole exon duplications and deletions. The
mechanism by which PRKN mutations exert a pathogenic effect is
not fully understood, but may involve loss of function and
inhibition of parkin’s ubiquitin E3 ligase activity and consequent
enhancement of neurodegeneration via impaired ubiquitination of
substrates [15]. In considering the role of PRKN variants in PD,
two main notions should be considered. First, heterozygous
mutations are fairly common in healthy subjects [13], and second,
the presence of an apparent single heterozygous mutation in a PD
patient typically should not rule out PRKN as the causative gene,
since other unscreened mutations may be present [16].
Machado-Joseph disease (MJD/ATXN3) is an autosomal
dominant progressive neurologic disorder characterized primarily
by ataxia, spasticity, and ocular movement abnormalities. The
disease is caused by a CAG repeat expansion in the gene ATXN3.
In 2001, Gwinn-Hardy and colleagues reported a family of sub-
Saharan African descent with several individuals displaying
parkinsonism suggestive of PD [7]. In this family the ATXN3
mutation segregated completely with the suggestive PD pheno-
type. Several cases of PD caused by repeat expansion mutation
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have been described in African-Americans, and it has been
suggested that genetic background may modulate the expressivity
of this mutation [17].
In spite of the upsurge in research and publications relating to
PD genetics in the past decade, much less is known about the
genetics of PD in the African subcontinent, with the majority of
publications to date focusing on the North African population
[18]. Understanding the genetic associations of PD in Africans will
improve our understanding of disease pathogenesis, and improve
decision making relating to the usefulness of commercially
available predictive genetic tests and preventive and therapeutic
interventions that may become available in the future. This study
reports the preliminary data from the screening of apparently
sporadic cases of PD from West Africa for LRRK2, PRKN and
ATXN3 mutations.
Methods
Population
The study protocol was approved by the Research and Ethics
Committee of the Lagos University Teaching Hospital, Lagos,
Nigeria. Written informed consent was obtained from all patients
and controls. Using a case-control design, 57 unrelated black
African PD patients (43 males and 14 females) aged 43 to 80 years
and 51 age-matched healthy individuals without a family history of
PD or tremor (35 males and 16 females; age range 42 to 87) were
recruited from sequentially attending patients at the Neurology
Out-patients clinic of the Lagos University Teaching Hospital,
Lagos, Nigeria. All patients were evaluated by a neurologist
specializing in movement disorders, with keen attention to
excluding patients with a possible secondary etiology. The PD
cases recruited were those with clinically definite PD only. The
inclusion criteria were the presence of all five of: a) at least two of
three cardinal signs of tremor, rigidity, bradykinesia (with or
without postural or gait abnormality); b) an asymmetric onset; c)
no identifiable secondary cause (e.g. repeated stroke, exposure to
medications capable of causing PD within 6 months before onset,
etc); d) responsiveness to levodopa therapy (applicable to treated
patients only); e) absence of signs of more extensive nervous system
involvement (e.g. early autonomic features or cognitive impair-
ment within 2 years of onset, otherwise unexplained corticospinal
tract dysfunction, and cerebellar signs). All PD cases were
evaluated using a standard protocol that included a historical
account, neurological examination, Unified Parkinson’s Disease
Rating Scale (UPDRS) assessment [19], Hoehn and Yahr staging
[20], and Folstein’s Mini Mental State examination [21]. Control
subjects had an abridged neurologic examination to exclude
parkinsonism, cognitive impairment, corticospinal tract dysfunc-
tion, or any overt neurologic illness. Saliva samples were collected
from each case and control using the Oragene kit (DNA Genotek).
The mean age at onset (based on patient’s or caregiver’s
recollection of age at onset of first cardinal symptom of PD) for this
group is 58.269.1 years (range 40–75). The majority of patients
presented no apparent family history for parkinsonism, while nine
presented at least one first-degree relative with a history of
tremors. This fact may suggest that, for these nine individuals, an
autosomal dominant mode of inheritance is possible. Hence, this
study will fail to rule out the possibility of mutations in one of the
known autosomal dominant PD genes, the SNCA gene.
Although all patients are from Nigeria, their specific ethnic
origins were as follows: Yoruba – 35 (61.4%), Igbo – 11 (19.3%),
and Edo (Ijaw/ Itsekiri/ Urhobo/ other south-south ethnicity) –
11 (19.3%). The ethnic origins of the controls were as follows:
Yoruba – 36 (70.6%), Igbo – 9 (17.6%), Edo – 5 (9.8%) and Hausa
– 1 (2%).
Further details of cases and controls are presented in Table 1.
Analysis of mutations
Genomic DNA was extracted from saliva using the Oragene kit
(DNA Genotek). PRKN, LRRK2 and ATXN3 were screened for
mutations. For PRKN, all exons and intron/exon boundaries were
polymerase chain reaction-amplified and sequenced in both
directions using BigDye chemistry (Applied Biosystems, Foster City,
CA) on an ABI3730xl as previously described [4]. PRKN mutations
are numbered according to GenBank accession number
NP_004553 for the protein (p.) and NM_004562 for the cDNA
Table 1. Clinical characteristics of PD cases and controls
Characteristic PD (n = 57) Controls (n = 51)
Age at study (mean6SD), years 62.369.1 63.768.7
Age at onset (mean6SD), years 58.269.1 N/A
Range of age at onset, years 40–75 N/A
Onset before age 50, n (%) 7 (12.3) N/A
Asymmetry of tremors or rigidity at onset, n (%) 57 (100) N/A
Bradykinesia, n (%) 57 (100) N/A
Parkinsonian tremor, n (%) 57 (100) N/A
Rigidity, n (%) 57 (100) N/A
Postural abnormality, n (%) 31 (54.4) N/A
Gait abnormality, n (%) 48 (84.2) N/A
Levodopa responsiveness, n (%)* 54 (94.7) N/A
MMSE [mean6SD (range)] 28.362.1 (19–30) N/A
Hoehn & Yahr stage [median (range)] 2 (1–4) N/A
UPDRS - motor subscale [mean6SD (range)] 35.1612.6 (10–66) N/A
Family history of tremors in a first-degree relative, n (%) 9 (15.8) N/A
*Levodopa responsiveness not applicable in 3 of the 57 who were pre-treatment cases.
doi:10.1371/journal.pone.0003421.t001
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(c.). LRRK2was screened by sequence analysis for the most common
mutations occurring in exons 31 and 41 as previously described [9].
ATXN3 pathogenic repeat expansion size was assessed in all samples
using methods described previously by us [17].
Copy number analysis
In addition to sequencing PRKN, we screened PRKN for copy
number mutations in two samples carrying heterozygous muta-
tions not found in controls (p.P153R; c.C458G and p.R334H;
c.G1001A), using the Illumina Infinium HumanHap550 Bead-
Chips (version 3; Illumina Inc, San Diego, CA, USA) as previously
described [22]. Copy number analysis by genotyping was done
according to the manufacturer’s protocol (Illumina Inc.) using 750
ng of genomic DNA. Data was analysed with BeadStudio v3
(Illumina Inc.) using the Human Genome build 35. Two metrics
were visualized using this tool, B allele frequency and log R ratio.
The former is the theta value for an individual SNP, which gives
an estimate of the proportion of times an individual allele at each
polymorphism is called A or B. The log R ratio is the log2 ratio of
the observed normalized R value for the SNP divided by the
expected normalized R value for the SNPs theta value. An R
above 1 is indicative of an increase in copy number, and values
below 1 suggest a deletion. We have shown previously that this is a
reliable method for detecting large genomic copy number
mutation in PRKN [22].
Results
We did not find any variants in exons 31 and 41 of LRRK2.
Likewise, the screening for the ATXN3 repeats revealed that no
samples contained pathogenic expansions. The PRKN gene yielded
several variants, some new and others previously described. With
the exception of the V380L and S167N polymorphisms, no other
missense homozygous variants were found. All the PRKN variants
are shown in Table 2. Additionally, samples that showed only one
heterozygous mutation in PRKN that was not present in controls
were screened for copy number variants in this gene, in order to
assess if these were in fact compound heterozygous for one point
and one genomic copy number mutation. Genomic copy number
analysis did not detect any mutations in these samples.
Discussion
This is the first study screening a sub-Saharan African cohort of
apparently sporadic PD cases for mutations in genes commonly
associated with PD. The results from this study are of clear
importance not only for Nigerian PD patients, but also because
they shed light on the genetic background associated with PD in
the African population. It should be noted that the number of
individuals included in this preliminary report is clearly small, and
thus, definite conclusions about frequencies of variants are difficult
to achieve.
We have performed a screening for the most common
autosomal recessive variants in three genes associated with PD
(LRRK2, PRKN and ATXN3). We decided not to screen for
mutations in the genes PINK1, DJ-1 and ATXN2 given the low
frequency of mutations in these genes in worldwide populations.
Moreover, we did not screen SNCA as mutations in this gene are
not only rare but they are also associated with an autosomal
dominant mode of inheritance. Given that the majority of our
patients have no affected family members with any form of
parkinsonism, mutations in SNCA would be unlikely to occur in
our cohort. Mutations in the LRRK2 are the most common cause
of PD in several populations, including populations of Northern-
African ancestry. In particular, Lesage and colleagues found a high
frequency (41%) of the G2019S mutation on exon 41 in a study of
North African Arabs that included both familial and apparently
sporadic PD cases [10]. Thus, it would be interesting to determine
if there is a similarly high frequency of LRRK2 G2019S mutations
in other geographically and ethnically distinct parts of Africa.
However, we did not find any mutations in either exons 31 and 41
of LRRK2 in our cohort, suggesting that mutations in these
domains of LRRK2 are not a common cause of PD in sub-Saharan
populations. A recent study performed a comprehensive analysis of
the entire coding region of LRRK2 in a large cohort of American
PD cases and healthy controls [23]. Of the seven mutations found
to be segregating with disease, five were in either exon 31 or exon
41, indicating these as clear mutational hotspots. The noteworthy
difference in mutation frequency among populations from the
same continent is, in all probability, due to the occurrence of the
founding G2019S mutation event happening after human
populations moved out of sub-Saharan Africa as this is most
consistent with the dating of this mutational event [24,25].
Parkinsonism due to ATXN3 repeat expansion mutation has
been previously described in one single large African descent
family. We failed to find any samples harboring the increased
repeat expansion size. This result suggests that ATXN3 repeat
expansion mutations are not a frequent cause of parkinsonism in
this population.
Even though a considerable number of PRKN mutations are
dosage mutations, the majority are sequence variants, hence, we
decided to perform the initial screen of our cohort only for these
variants. Subsequently, we performed gene dosage analysis in two
samples as previously detailed. Again, our study did not identify
any pathogenic mutations in PRKN in our subset of PD patients.
We found several heterozygous variants both in patients and
controls.,Two of the variants are novel and present only in PD
cases (p.R334H and p.A46T). Given the fact that these are novel
variants, we ran the analysis software SIFT (available at http://
blocks.fhcrc.org/sift/) [26] in order to have some insight into the
Table 2. PARK2 gene variants in PD cases and controls
Gene
Heterozygous
variants Parkinson’s disease Control group
N (%) N (%)
PARK2 p.E16E; c.G48T 3 (5.3) 1 (2.0)
p.P37P; c.G111A 8 (14.0) 6 (11.8)
p.A46T; c.G136A 1 (1.8) 0
p.P153R; c.C458G 0 1 (2.0)
p.S167N; c.G500A 4 (7.0) 4 (7.8)
p.M192L; c.A574G 7 (12.3) 6 (11.8)
p.L261L; c.A783G 13 (22.8) 14 (27.4)
p.G319G; c.T957C 5 (8.8) 4 (7.8)
p.R334H; c.G1001A 1 (1.8) 0
p.V380L; c.G1138A 2 (3.5) 3 (5.9)
Homozygous
variants
p.P37P; c.G111A 1 (1.8) 3 (5.9)
p.S167N; c.G500A 1 (1.8) 0
p.L261L; c.A783G 1 (1.8) 3 (5.9)
p.V380L; c.G1138A 1 (1.8) 1 (2.0)
doi:10.1371/journal.pone.0003421.t002
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potential effects of these variants. The p.A46T was predicted by
the software to potentially affect protein function, whereas the
p.R334H was predicted to have no functional effect. However,
these results are merely based on a similarity score in comparison
to other proteins, and hence it must be stressed that this is not true
functional data for these variants. Nonetheless, in the absence of a
second mutation, these cannot be described as pathogenic, thus we
decided to classify these as variants of unknown pathogenicity. It
should be noted that for these two samples, an additional screen
for gene dosage mutations was performed using the Illumina
BeadChips. In addition, one homozygous variant was found only
in the PD group (p.S167N; c.G500A). However, this has
previously been classified as a polymorphism [12,13].
All populations showed polymorphisms with varying frequen-
cies. Three variants p.A46T, p.P153R and p.R334H were found
in a single sample each. Variant p.A46T was present in one PD
sample from Igbo, p.P153R was found in a Yoruban sample, and
p.R334H was present in a sample with Edo background. Two
individuals, both from the same ethnic region (Edo), presented
with two missense variants each (p.M129L and p.S167N;
p.M129L and p.V380L). Although the present study cannot
completely rule out that these compound hetererozygous events
could potentially be pathogenic, two facts suggest otherwise: 1) in
each case the second variant is a well known and described SNP;
2) one control sample presented the same combination of two of
the variants (p.M129L and p.V380L).
We report the first genetic screening for PD genes in a sub-
Saharan population. We found no pathogenic mutations in the
genes most commonly known to cause PD in European North
American, or North African populations. Although the cohort
studied is clearly small and definite conclusions regarding
frequencies are unachievable, a trend for different genetic basis
of PD in this sub-Saharan population is, in our opinion,
noteworthy. Two main caveats are present in this work: gene
dosage mutations in PRKN were only screened for in two samples
and only exons 31 and 41 of LRRK2 were sequenced. Nevertheless,
the aim of this study was to ascertain a preliminary frequency of
the most common variants known to cause PD in a sub-Saharan
population. We report here that the most common variant
associated with PD in several world-wide populations, the
p.G2019S mutation in LRRK2, is not overrepresented in this
Nigerian population of PD patients; similarly, sequence variants in
PRKN, which represent a significant proportion of PRKN
mutations underlying PD, are also not significantly present in
the studied cohort. It is thus likely that the differences in the
genetic background of these populations mean that other genes or
different variants are underlying the disease. Therefore, a search
for these is clearly warranted, since they will, in all probability,
shed more light on different pathways leading to PD.
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